Literature DB >> 25894288

Psychosis in Parkinson's disease: identification, prevention and treatment.

Johannes Levin1, Alkomiet Hasan2, Günter U Höglinger3,4.   

Abstract

Psychosis in Parkinson's disease (PD) is a frequent condition affecting >20 % of all PD patients. It is characterized by vivid dreams, nightmares, illusions, delusions and mostly visual hallucinations. Typically psychosis occurs in the late stage of PD, affecting up to 70 % of the patients following a disease duration of 20 years or more, and can severely interfere with the care of the patients, especially if the patients develop delusions. Psychosis is the principal cause of admission to a nursing home for PD patients. Hence, preemptive identification of risk factors, and avoidance and elimination of triggers are most important measures against psychosis in PD patients. Secondarily, pharmaceutical measures are being undertaken successively, including simplification of medication regimes, discontinuation of non-essential CNS-active drugs, ordered reduction of antiparkinsonian drugs, addition of cholesterinase inhibitors in cognitively impaired patients, and finally addition of antipsychotic medication with limited parkinsonian side effects. As psychosis in PD is a frequent and important problem, we set out to write a state-of-the-art guideline for its identification and treatment.

Entities:  

Keywords:  Dopamine; Hallucination; Parkinson’s disease; Psychosis

Mesh:

Substances:

Year:  2015        PMID: 25894288     DOI: 10.1007/s00702-015-1400-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  34 in total

Review 1.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

Authors:  S Kapur; P Seeman
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

2.  The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

Review 3.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

Review 4.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

5.  Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.

Authors:  P J Whitehouse
Journal:  Adv Neurol       Date:  1987

6.  Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms.

Authors:  Angela H Lee; Daniel Weintraub
Journal:  Mov Disord       Date:  2012-06-01       Impact factor: 10.338

7.  Scales to assess psychosis in Parkinson's disease: Critique and recommendations.

Authors:  Hubert H Fernandez; Dag Aarsland; Gilles Fénelon; Joseph H Friedman; Laura Marsh; Alexander I Tröster; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2008-03-15       Impact factor: 10.338

8.  Risk factors for visual hallucinations in patients with Parkinson's disease.

Authors:  Rômulo Lopes Gama; Veralice Meireles Sales de Bruin; Pedro Felipe Carvalhedo de Bruin; Daniel Gurgel Fernandes Távora; Emily Mourão Soares Lopes; Iago Farias Jorge; Lia Rita Azeredo Bittencourt; Sergio Tufik
Journal:  Neurol Res       Date:  2014-07-08       Impact factor: 2.448

Review 9.  In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

Authors:  Herbert Y Meltzer; Mei Huang
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

10.  Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study.

Authors:  Hideyuki Sawada; Tomoko Oeda; Kenji Yamamoto; Atsushi Umemura; Satoshi Tomita; Ryutaro Hayashi; Masayuki Kohsaka; Takashi Kawamura
Journal:  BMC Neurol       Date:  2013-10-12       Impact factor: 2.474

View more
  11 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 2.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

3.  Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.

Authors:  M Ferrari; C Comi; F Marino; L Magistrelli; F De Marchi; R Cantello; G Riboldazzi; G Bono; M Cosentino
Journal:  Eur J Clin Pharmacol       Date:  2016-08-06       Impact factor: 2.953

4.  Nonlinear parameters of surface EMG in schizophrenia patients depend on kind of antipsychotic therapy.

Authors:  Alexander Yu Meigal; German G Miroshnichenko; Anna P Kuzmina; Saara M Rissanen; Stefanos D Georgiadis; Pasi A Karjalainen
Journal:  Front Physiol       Date:  2015-07-10       Impact factor: 4.566

5.  Increased risk of falls and fractures in patients with psychosis and Parkinson disease.

Authors:  Joan Forns; J Bradley Layton; Jennifer Bartsch; Mary Ellen Turner; Colleen Dempsey; Mary Anthony; Mary E Ritchey; George Demos
Journal:  PLoS One       Date:  2021-01-27       Impact factor: 3.240

6.  A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey.

Authors:  Katie McGoohan; Anneesa Amjad; Natasha Ratcliffe; Sagnik Bhattacharyya; Gillian Granville; Matthew Sullivan; Lesley Gosden; Dag Aarsland; K Ray Chaudhuri; Dominic Ffytche; Clive Ballard; Latha Velayudhan
Journal:  Front Psychiatry       Date:  2020-12-23       Impact factor: 4.157

7.  Mapping brain structural differences and neuroreceptor correlates in Parkinson's disease visual hallucinations.

Authors:  Miriam Vignando; Dominic Ffytche; Simon J G Lewis; Phil Hyu Lee; Seok Jong Chung; Rimona S Weil; Michele T Hu; Clare E Mackay; Ludovica Griffanti; Delphine Pins; Kathy Dujardin; Renaud Jardri; John-Paul Taylor; Michael Firbank; Grainne McAlonan; Henry K F Mak; Shu Leong Ho; Mitul A Mehta
Journal:  Nat Commun       Date:  2022-01-26       Impact factor: 17.694

Review 8.  QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.

Authors:  Yasar Torres-Yaghi; Amelia Carwin; Jacob Carolan; Steven Nakano; Fahd Amjad; Fernando Pagan
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-24       Impact factor: 2.570

Review 9.  Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.

Authors:  Raquel N Taddei; Seyda Cankaya; Sandeep Dhaliwal; K Ray Chaudhuri
Journal:  Parkinsons Dis       Date:  2017-09-12

10.  Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study.

Authors:  Naveed Malek; Rimona S Weil; Catherine Bresner; Michael A Lawton; Katherine A Grosset; Manuela Tan; Nin Bajaj; Roger A Barker; David J Burn; Thomas Foltynie; John Hardy; Nicholas W Wood; Yoav Ben-Shlomo; Nigel W Williams; Donald G Grosset; Huw R Morris
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-01-29       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.